RenovoRx Inc
RNXT
Company Profile
Business description
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
Contact
2570 West El Camino Real
Suite 320
Mountain ViewCA94040
USAT: +1 650 284-4433
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
17
Stocks News & Analysis
stocks
Older cohorts the budget losers, not necessarily the ASX listed insurers
Proposed legislation removes health insurance rebates.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,717.00 | 82.40 | -0.94% |
| CAC 40 | 8,006.76 | 25.00 | 0.31% |
| DAX 40 | 24,444.41 | 43.76 | 0.18% |
| Dow JONES (US) | 49,363.88 | 322.24 | -0.65% |
| FTSE 100 | 10,320.59 | 9.96 | -0.10% |
| HKSE | 25,651.12 | 146.73 | -0.57% |
| NASDAQ | 25,870.71 | 220.02 | -0.84% |
| Nikkei 225 | 59,804.41 | 746.18 | -1.23% |
| NZX 50 Index | 12,761.03 | 213.29 | -1.64% |
| S&P 500 | 7,353.61 | 49.44 | -0.67% |
| S&P/ASX 200 | 8,496.60 | 76.50 | -0.89% |
| SSE Composite Index | 4,162.18 | 7.35 | -0.18% |